SavedAdd your journal

Journals / Cukurova Medical Journal / 2021 / Cilt: 46 - Sayı: 3

Importance of circulating microRNA-122 for hepatocellular carcinoma

Hepatoselüler karsinomda serum mikroRNA-122'nin önemi

Engin ONAN
Hikmet AKKIZ
Macit Umran SANDIKCI
Oğuz ÜSKÜDAR
Agah Bahadır ÖZTÜRK
Pages
1300–1308
Publication Date
2021-09-30
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Results: Serum miR-122 levels were found significantly higher in hepatocellular carcinoma patients compared to the control group. (median miR-122 (min. – max.); patients: 0.0104 (0-0.262); controls: 0.00187 (0-0.100), p

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Purpose: The main purpose of our study is to research the potential of circulating microRNA-122 (miR-122)as a marker for hepatocellular carcinoma.
📊
Key Findings & Data:Materials and Methods: Circulating miR-122 levels were measured by real-time polymerase chain reaction in patients with varied stages of hepatocellular carcinoma.
💡
Conclusion & Impact:Results: Serum miR-122 levels were found significantly higher in hepatocellular carcinoma patients compared to the control group. (median miR-122 (min. – max.); patients: 0.0104 (0-0.262); controls: 0.00187 (0-0.100), p
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Hepatoselüler karsinom · serum microRNA-122. · microRNA-122

Abstract

Purpose: The main purpose of our study is to research the potential of circulating microRNA-122 (miR-122)as a marker for hepatocellular carcinoma. Materials and Methods: Circulating miR-122 levels were measured by real-time polymerase chain reaction in patients with varied stages of hepatocellular carcinoma. In addition, various other laboratory and clinical data of the participants were evaluated in order to observe the correlation between these data and serum miR-122 levels. Results: Serum miR-122 levels were found significantly higher in hepatocellular carcinoma patients compared to the control group. (median miR-122 (min. – max.); patients: 0.0104 (0-0.262); controls: 0.00187 (0-0.100), p

Özet

Amaç: Bu çalışmanın amacı, hepatoselüler karsinomda dolaşımdaki mikroRNA-122'nin (miR-122) biyobelirteç olarak potansiyelini araştırmaktır. Gereç ve Yöntem: Bu çalışmada, dolaşımdaki miR-122 seviyeleri, hepatoselüler karsinomun farklı klinik evreleri olan hastalarda gerçek zamanlı polimeraz zincir reaksiyonu ile ölçülmüştür. Ayrıca, bu veriler ile serum miR-122 seviyeleri arasındaki korelasyonu gözlemlemek için diğer laboratuvar ve klinik veriler de değerlendirilmiştir. Bulgular: Hepatoselüler karsinom hastalarında serum miR-122 seviyeleri kontrol grubuna göre anlamlı olarak yüksek bulundu. (medyan miR-122 (min. - maks.); hastalar: 0,0104 (0-0,262); kontroller: 0,00187 (0-0,100), p

🔖

Cite This Article

ONAN, E., AKKIZ, H., SANDIKCI, M. U., ÜSKÜDAR, O., ÖZTÜRK, A. B. (2021). Importance of circulating microRNA-122 for hepatocellular carcinoma. Cukurova Medical Journal, Cilt: 46 - Sayı: 3, 1300–1308. https://ajindex.com/articles/482218

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (14)

  1. Referans 1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018
  2. Referans 2. Rawla P, Sunkara T, Muralidharan P, Raj JP. Update in global trends and aetiology of hepatocellular carcinoma. Contemp Oncol (Pozn). 2018
  3. Referans 3. Petrick JL, McGlynn KA. The changing epidemiology of primary liver cancer. Curr Epidemiol Rep. 2019
  4. Referans 4. Yang JD, Hainaut P, Gores GJ, Amadou A, Plymoth A, Roberts LR. A global view of hepatocellular carcinoma: trends, risk, prevention and management. Nat Rev Gastroenterol Hepatol. 2019
  5. Referans 5. Sagnelli E, Macera M, Russo A, Coppola N, Sagnelli C. Epidemiological and etiological variations in hepatocellular carcinoma. Infection. 2020
  6. Referans 6. Zinkin NT, Grall F, Bhaskar K et al. Serum proteomics and biomarkers in hepatocellular carcinoma and chronic liver disease. Clin Cancer Res. 2008
  7. Referans 7. Berezikov E, Guryev V, van de Belt J, Wienholds E, Plasterk RH, Cuppen E. Phylogenetic shadowing and computational identification of human microRNA genes. Cell. 2005
  8. Referans 8. Zhang HH, Wang XJ, Li GX, Yang E, Yang NM. Detection of let-7a microRNA by real-time PCR in gastric carcinoma. World J Gastroenterol. 2007
  9. Referans 9. Cortez MA, Calin GA. MicroRNA identification in plasma and serum: a new tool to diagnose and monitor diseases. Expert Opin Biol Ther. 2009
  10. Referans 10. Chen X, Ba Y, Ma L et al. Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases. Cell Res. 2008
  11. Referans 11. Hu Z, Chen X, Zhao Y et al. Serum microRNA signatures identified in a genome-wide serum microRNA expression profiling predict survival of non-small-cell lung cancer. J Clin Oncol. 2010
  12. Referans 12. Ladeiro Y, Couchy G, Balabaud C et al. MicroRNA profiling in hepatocellular tumors is associated with clinical features and oncogene/tumor suppressor gene mutations. Hepatol. 2008
  13. Referans 13. Varnholt H, Drebber U, Schulze F et al. MicroRNA gene expression profile of hepatitis C virus-associated hepatocellular carcinoma. Hepatol. 2008
  14. Referans 14. Coulouarn C, Factor VM, Andersen JB, Durkin ME, Thorgeirsson SS. Loss of miR-122 expression in liver cancer correlates with suppression of the hepatic phenotype